Insider Selling: BioSyent (CVE:RX) Director Sells C$47,995.00 in Stock

BioSyent Inc. (CVE:RX) Director Seyed Ahmad Ashrafi sold 2,900 shares of the company’s stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of C$16.55, for a total value of C$47,995.00. Following the sale, the director owned 21,461 shares of the company’s stock, valued at C$355,179.55. This trade represents a 11.90% decrease in their position.

Seyed Ahmad Ashrafi also recently made the following trade(s):

• On Monday, September 21st, Seyed Ahmad Ashrafi sold 300 shares of BioSyent stock. The shares were sold at an average price of C$16.05, for a total transaction of C$4,815.00.
• On Tuesday, September 22nd, Seyed Ahmad Ashrafi sold 700 shares of BioSyent stock. The stock was sold at an average price of C$16.20, for a total transaction of C$11,340.00.
• On Tuesday, September 22nd, Seyed Ahmad Ashrafi sold 1,000 shares of BioSyent stock. The stock was sold at an average price of C$16.75, for a total transaction of C$16,750.00.
• On Wednesday, September 2nd, Seyed Ahmad Ashrafi sold 100 shares of BioSyent stock. The stock was sold at an average price of C$16.00, for a total transaction of C$1,600.00.
• On Thursday, September 3rd, Seyed Ahmad Ashrafi sold 700 shares of BioSyent stock. The shares were sold at an average price of C$16.00, for a total transaction of C$11,200.00.
• On Tuesday, June 30th, Seyed Ahmad Ashrafi sold 1,884 shares of BioSyent stock. The shares were sold at an average price of C$14.65, for a total transaction of C$27,600.60.
• On Tuesday, June 30th, Seyed Ahmad Ashrafi sold 800 shares of BioSyent stock. The shares were sold at an average price of C$14.70, for a total value of C$11,760.00.
• On Tuesday, June 30th, Seyed Ahmad Ashrafi sold 600 shares of BioSyent stock. The stock was sold at an average price of C$14.50, for a total value of C$8,700.00.

BioSyent Stock Performance

CVE RX traded down C$0.35 on Friday, hitting C$16.20. 6,290 shares of the company’s stock were exchanged, compared to its average volume of 8,279. The firm has a market cap of C$183.21 million, a price-to-earnings ratio of 18.97 and a beta of 1.11. The firm’s 50-day moving average price is C$15.43 and its two-hundred day moving average price is C$14.85. BioSyent Inc. has a fifty-two week low of C$10.65 and a fifty-two week high of C$17.50. The company has a debt-to-equity ratio of 6.85, a current ratio of 2.07 and a quick ratio of 6.91.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.